APA (7th ed.) Citation

Cui, Y., Qiu, T., Wang, J., Liu, X., Luo, L., Yin, J., . . . Ren, S. IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC. BMC.

Chicago Style (17th ed.) Citation

Cui, Yanan, et al. IFITM3 Enhances Immunosensitivity via MHC-I Regulation and Is Associated with the Efficacy of Anti-PD-1/-L1 Therapy in SCLC. BMC.

MLA (9th ed.) Citation

Cui, Yanan, et al. IFITM3 Enhances Immunosensitivity via MHC-I Regulation and Is Associated with the Efficacy of Anti-PD-1/-L1 Therapy in SCLC. BMC.